A Phase 1/2, First-in-Human, Open-Label, Dose Escalation Study of Talquetamab, a Humanized GPRC5D x CD3 Bispecific Antibody, in Subjects With Relapsed or Refractory Multiple Myeloma
A Phase 1/2, First-in-Human, Open-Label, Dose Escalation Study of Talquetamab, a Humanized GPRC5D x CD3 Bispecific Antibody, in Subjects With Relapsed or Refractory Multiple Myeloma
The purpose of this study is to evaluate the efficacy and safety of talquetamab in participants with relapsed or refractory multiple myeloma at the recommended Phase 2 dose(s) (RP2Ds) (Part 3).
Inclusion Criteria:
Exclusion Criteria:
Participate-In-This-Study1@its.jnj.com844-434-4210
Hangzhou, 310003, China
Hangzhou, 310003, China
Tianjin, 300320, China
Hokkaido, 006-8555, Japan
Matsumoto, 399-8701, Japan
Ōtake, 739-0696, Japan
Shiwa-gun, 028-3695, Japan
Gliwice, 44102, Poland
Warsaw, 02-781, Poland
Wroclaw, 50 367, Poland
Jeollanam-do, 58128, South Korea